Shanghai Kaibao Pharmaceutical (300039) - Total Liabilities
Based on the latest financial reports, Shanghai Kaibao Pharmaceutical (300039) has total liabilities worth CN¥412.55 Million CNY (≈ $60.37 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Shanghai Kaibao Pharmaceutical net asset momentum to track the company's year-over-year net asset growth rate.
Shanghai Kaibao Pharmaceutical - Total Liabilities Trend (2006–2024)
This chart illustrates how Shanghai Kaibao Pharmaceutical's total liabilities have evolved over time, based on quarterly financial data. See 300039 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Shanghai Kaibao Pharmaceutical Competitors by Total Liabilities
The table below lists competitors of Shanghai Kaibao Pharmaceutical ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Lloyds Banking Group PLC
LSE:LLOY
|
UK | GBX891.83 Billion |
|
Heilongjiang ZBD Pharmaceutical Co Ltd
SHG:603567
|
China | CN¥4.51 Billion |
|
Seegene Inc
KQ:096530
|
Korea | ₩214.46 Billion |
|
Empire State Realty Trust Inc
NYSE:ESRT
|
USA | $2.31 Billion |
|
Beijing New Space Technology Co Ltd
SHG:605178
|
China | CN¥519.13 Million |
|
Dynavox Group
ST:DYVOX
|
Sweden | Skr1.86 Billion |
|
Navigator Global Investments Ltd
AU:NGI
|
Australia | AU$164.23 Million |
|
Shanghai Prisemi Electronics Co Ltd
SHG:688230
|
China | CN¥58.91 Million |
Liability Composition Analysis (2006–2024)
This chart breaks down Shanghai Kaibao Pharmaceutical's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Shanghai Kaibao Pharmaceutical.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shanghai Kaibao Pharmaceutical's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shanghai Kaibao Pharmaceutical (2006–2024)
The table below shows the annual total liabilities of Shanghai Kaibao Pharmaceutical from 2006 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥415.45 Million ≈ $60.79 Million |
-24.02% |
| 2023-12-31 | CN¥546.82 Million ≈ $80.02 Million |
+9.75% |
| 2022-12-31 | CN¥498.24 Million ≈ $72.91 Million |
+60.25% |
| 2021-12-31 | CN¥310.90 Million ≈ $45.50 Million |
+4.00% |
| 2020-12-31 | CN¥298.96 Million ≈ $43.75 Million |
+9.51% |
| 2019-12-31 | CN¥273.01 Million ≈ $39.95 Million |
+4.10% |
| 2018-12-31 | CN¥262.26 Million ≈ $38.38 Million |
-16.55% |
| 2017-12-31 | CN¥314.26 Million ≈ $45.99 Million |
-4.07% |
| 2016-12-31 | CN¥327.61 Million ≈ $47.94 Million |
-22.21% |
| 2015-12-31 | CN¥421.16 Million ≈ $61.63 Million |
+80.97% |
| 2014-12-31 | CN¥232.72 Million ≈ $34.05 Million |
+41.29% |
| 2013-12-31 | CN¥164.72 Million ≈ $24.10 Million |
+15.76% |
| 2012-12-31 | CN¥142.29 Million ≈ $20.82 Million |
+20.61% |
| 2011-12-31 | CN¥117.97 Million ≈ $17.26 Million |
-11.56% |
| 2010-12-31 | CN¥133.39 Million ≈ $19.52 Million |
-33.04% |
| 2009-12-31 | CN¥199.20 Million ≈ $29.15 Million |
+93.49% |
| 2008-12-31 | CN¥102.95 Million ≈ $15.06 Million |
+21.63% |
| 2007-12-31 | CN¥84.64 Million ≈ $12.39 Million |
+17.89% |
| 2006-12-31 | CN¥71.80 Million ≈ $10.51 Million |
-- |
About Shanghai Kaibao Pharmaceutical
Shanghai Kaibao Pharmaceutical CO.,Ltd engages in the research, development, production, and sale of modern traditional Chinese medicines primarily in China. The company offers heat-clearing and detoxifying products, such as Tanreqing Injection for wind-heat in the lungs with phlegm-heat obstructing the lungs, early-stage pneumonia, acute bronchitis, acute exacerbations of chronic bronchitis, and… Read more